Wijesurendra Dinidu S, Kanci Anna, Tivendale Kelly A, Devlin Joanne M, Wawegama Nadeeka K, Bacci Barbara, Noormohammadi Amir H, Markham Philip F, Browning Glenn F
a Asia-Pacific Centre for Animal Health, Faculty of Veterinary and Agricultural Sciences , The University of Melbourne , Parkville , Australia.
b Asia-Pacific Centre for Animal Health, Faculty of Veterinary and Agricultural Sciences , The University of Melbourne , Werribee , Australia.
Avian Pathol. 2017 Oct;46(5):464-473. doi: 10.1080/03079457.2017.1311990. Epub 2017 Apr 20.
Infection with Mycoplasma gallisepticum induces severe lymphoproliferative lesions in multiple sites along the respiratory tract in chickens and turkeys. These immunopathological responses have been well-characterized in chickens, but have not been studied closely in turkeys. The aim of the study described here was to examine the immune responses of turkeys after live vaccination and infection with M. gallisepticum. In a strain comparison study, the mean log antibody titre of birds exposed to an aerosol culture of M. gallisepticum strain Ap3AS was found to be significantly higher at day 14 than that of birds exposed to strain 100809/31. In a dose-response study, there was a significant difference in the mean log antibody titre between birds exposed to mycoplasma broth and birds exposed to the highest dose of strain Ap3AS at day 7 after exposure. Immunohistochemical analysis of the tracheal mucosa and the air sacs revealed similar patterns of distribution of CD4 and CD8 lymphocytes to those seen in the tracheal mucosa of chickens, implicating these cell types in the pathogenesis of respiratory mycoplasmosis in turkeys. Turkeys that had been vaccinated with M. gallisepticum GapA ts-11 had significantly higher antibody titres than unvaccinated birds at both 7 and 14 days after challenge with strain Ap3AS. Vaccination with GapA ts-11 protected against the lymphoproliferative response to infection with virulent M. gallisepticum in both the tracheal mucosa and the air sacs, suggesting that this strain may be a useful vaccine candidate for use in turkeys.
感染鸡毒支原体可在鸡和火鸡呼吸道的多个部位诱发严重的淋巴增生性病变。这些免疫病理反应在鸡中已得到充分表征,但在火鸡中尚未进行深入研究。本文所述研究的目的是检测火鸡在活疫苗接种和感染鸡毒支原体后的免疫反应。在一项品系比较研究中,发现暴露于鸡毒支原体Ap3AS品系气溶胶培养物的鸡在第14天的平均对数抗体滴度显著高于暴露于100809/31品系的鸡。在一项剂量反应研究中,暴露于支原体肉汤的鸡与暴露于Ap3AS品系最高剂量的鸡在暴露后第7天的平均对数抗体滴度存在显著差异。气管黏膜和气囊的免疫组织化学分析显示,CD4和CD8淋巴细胞的分布模式与鸡气管黏膜中的相似,表明这些细胞类型参与了火鸡呼吸道支原体病的发病机制。用鸡毒支原体GapA ts-11疫苗接种的火鸡在受到Ap3AS品系攻击后第7天和第14天的抗体滴度均显著高于未接种疫苗的火鸡。用GapA ts-11疫苗接种可预防气管黏膜和气囊对强毒鸡毒支原体感染的淋巴增生反应,表明该品系可能是一种用于火鸡的有用疫苗候选株。